Tesamorelin Study Index
Tesamorelin (TH9507) is a synthetic analog of full-length human GHRH(1-44), stabilized by the addition of a trans-2 hexenoic acid moiety at the N-terminus to improve metabolic stability. It activates the GHRH receptor on pituitary somatotroph cells to stimulate GH release in a manner that preserves the physiological somatostatin-mediated negative feedback loop, resulting in amplified but normally patterned GH pulses rather than sustained supraphysiological GH elevation. Tesamorelin received FDA approval in 2010 (as Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, making it one of the few peptide growth hormone secretagogues with Phase 3 clinical trial data and regulatory approval.
Studies Listed
6
Curated Study References
Click column headers to sort. PubMed links open in a new tab where available.
| Authors ↕ | Year ↓ | Journal ↕ | Key Finding | PubMed |
|---|---|---|---|---|
| Fourman et al. | 2020 | Journal of Clinical Endocrinology and Metabolism | Tesamorelin reduced liver fat content and hepatic inflammatory markers in HIV patients with metabolic complications, with some effects occurring through mechanisms that did not depend solely on GH or IGF-1 elevation, broadening the mechanistic understanding of its metabolic effects. | 31855248 ↗ |
| Spooner et al. | 2013 | AIDS Research and Human Retroviruses | Extended open-label follow-up data demonstrated that visceral fat reduction achieved with Tesamorelin was substantially maintained during continued treatment but reversed after discontinuation, characterizing the duration-dependence of its body composition effects. | 23281999 ↗ |
| Stanley et al. | 2012 | Journal of Clinical Endocrinology and Metabolism | Tesamorelin produced significant visceral fat reduction and improvements in triglyceride levels compared to placebo over 52 weeks in HIV-infected men with central adiposity, with effects on body composition maintained throughout the treatment period. | 22162468 ↗ |
| Grinspoon et al. | 2012 | AIDS | Long-term 52-week Tesamorelin treatment produced sustained visceral fat reduction and improved lipid profiles in HIV-infected patients, demonstrating durable efficacy over a clinically relevant treatment period. | 22343177 ↗ |
| Dhindsa et al. | 2011 | JAIDS | Tesamorelin treatment selectively reduced large VLDL particle concentrations and improved LDL particle size distribution in HIV lipodystrophy patients, demonstrating lipid-level metabolic benefits beyond visceral fat reduction. | 21869715 ↗ |
| Falutz et al. | 2010 | New England Journal of Medicine | Phase 3 double-blind trial demonstrating that Tesamorelin significantly reduced visceral adipose tissue by approximately 15 to 18 percent compared to placebo in HIV-infected patients with lipodystrophy, supporting the FDA approval of Egrifta. | 20581395 ↗ |
Fourman et al.
2020, Journal of Clinical Endocrinology and Metabolism
Tesamorelin reduced liver fat content and hepatic inflammatory markers in HIV patients with metabolic complications, with some effects occurring through mechanisms that did not depend solely on GH or IGF-1 elevation, broadening the mechanistic understanding of its metabolic effects.
Spooner et al.
2013, AIDS Research and Human Retroviruses
Extended open-label follow-up data demonstrated that visceral fat reduction achieved with Tesamorelin was substantially maintained during continued treatment but reversed after discontinuation, characterizing the duration-dependence of its body composition effects.
Stanley et al.
2012, Journal of Clinical Endocrinology and Metabolism
Tesamorelin produced significant visceral fat reduction and improvements in triglyceride levels compared to placebo over 52 weeks in HIV-infected men with central adiposity, with effects on body composition maintained throughout the treatment period.
Grinspoon et al.
2012, AIDS
Long-term 52-week Tesamorelin treatment produced sustained visceral fat reduction and improved lipid profiles in HIV-infected patients, demonstrating durable efficacy over a clinically relevant treatment period.
Dhindsa et al.
2011, JAIDS
Tesamorelin treatment selectively reduced large VLDL particle concentrations and improved LDL particle size distribution in HIV lipodystrophy patients, demonstrating lipid-level metabolic benefits beyond visceral fat reduction.
Falutz et al.
2010, New England Journal of Medicine
Phase 3 double-blind trial demonstrating that Tesamorelin significantly reduced visceral adipose tissue by approximately 15 to 18 percent compared to placebo in HIV-infected patients with lipodystrophy, supporting the FDA approval of Egrifta.
All citations are for informational research reference purposes. Always verify directly via PubMed for current status.
Research Questions
Common questions about Tesamorelin research context, mechanism, and procurement.
What is Tesamorelin and how does it differ from synthetic GHRH?+
What FDA approval data exists for Tesamorelin?+
What long-term body composition research exists for Tesamorelin?+
What liver-related research has been conducted on Tesamorelin?+
Related Compound Comparisons
Explore how Tesamorelin compares to other research compounds.
Source Tesamorelin
Tesamorelin is available from Spartan Peptides at least 98% HPLC-verified purity. Domestic US supply with same-day dispatch before 2 PM. For in-vitro research use only.
Order Tesamorelin ($159)For in-vitro research use only. Not intended for human consumption.